These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 19356612)

  • 21. Antibodies and CD4(+) T-cells mediate cross-protection against H5N1 influenza virus infection in mice after vaccination with a low pathogenic H5N2 strain.
    Droebner K; Haasbach E; Fuchs C; Weinzierl AO; Stevanovic S; Büttner M; Planz O
    Vaccine; 2008 Dec; 26(52):6965-74. PubMed ID: 18848593
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Preclinical evaluation of a modified vaccinia virus Ankara (MVA)-based vaccine against influenza A/H5N1 viruses.
    Kreijtz JH; Suezer Y; de Mutsert G; van den Brand JM; van Amerongen G; Schnierle BS; Kuiken T; Fouchier RA; Löwer J; Osterhaus AD; Sutter G; Rimmelzwaan GF
    Vaccine; 2009 Oct; 27(45):6296-9. PubMed ID: 19840663
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Study on immunogenicity of a recombinant adenovirus vaccine containing neuraminidase gene of H5N1 influenza virus (A/Anhui/1/2005) in mice].
    Ma J; Zhang XG; Li KB; Zhang XM; Wang M; Bai T; Yang L; Xu H; Shu YL; Zeng Y
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2009 Dec; 23(6):449-51. PubMed ID: 20718353
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Needle-free skin patch delivery of a vaccine for a potentially pandemic influenza virus provides protection against lethal challenge in mice.
    Garg S; Hoelscher M; Belser JA; Wang C; Jayashankar L; Guo Z; Durland RH; Katz JM; Sambhara S
    Clin Vaccine Immunol; 2007 Jul; 14(7):926-8. PubMed ID: 17494637
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Registration of the first human vaccine against the highly pathogenic avian influenza A(H5N1) virus: considerations].
    de Jong JC; Osterhaus AD
    Ned Tijdschr Geneeskd; 2008 Sep; 152(39):2113-5. PubMed ID: 18856026
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long lasting immunity in chickens induced by a single shot of influenza vaccine prepared from inactivated non-pathogenic H5N1 virus particles against challenge with a highly pathogenic avian influenza virus.
    Sasaki T; Kokumai N; Ohgitani T; Sakamoto R; Takikawa N; Lin Z; Okamatsu M; Sakoda Y; Kida H
    Vaccine; 2009 Aug; 27(38):5174-7. PubMed ID: 19596414
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunogenicity, safety, and cross-reactivity of an inactivated, adjuvanted, prototype pandemic influenza (H5N1) vaccine: a phase II, double-blind, randomized trial.
    Wu J; Fang HH; Chen JT; Zhou JC; Feng ZJ; Li CG; Qiu YZ; Liu Y; Lu M; Liu LY; Dong SS; Gao Q; Zhang XM; Wang N; Yin WD; Dong XP
    Clin Infect Dis; 2009 Apr; 48(8):1087-95. PubMed ID: 19281330
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Multi-antigen vaccines based on complex adenovirus vectors induce protective immune responses against H5N1 avian influenza viruses.
    Holman DH; Wang D; Raja NU; Luo M; Moore KM; Woraratanadharm J; Mytle N; Dong JY
    Vaccine; 2008 May; 26(21):2627-39. PubMed ID: 18395306
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intramuscular Matrix-M-adjuvanted virosomal H5N1 vaccine induces high frequencies of multifunctional Th1 CD4+ cells and strong antibody responses in mice.
    Madhun AS; Haaheim LR; Nilsen MV; Cox RJ
    Vaccine; 2009 Dec; 27(52):7367-76. PubMed ID: 19781678
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The novel adjuvant CoVaccineHT increases the immunogenicity of cell-culture derived influenza A/H5N1 vaccine and induces the maturation of murine and human dendritic cells in vitro.
    Bodewes R; Geelhoed-Mieras MM; Heldens JG; Glover J; Lambrecht BN; Fouchier RA; Osterhaus AD; Rimmelzwaan GF
    Vaccine; 2009 Nov; 27(49):6833-9. PubMed ID: 19772942
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparative efficacy of North American and antigenically matched reverse genetics derived H5N9 DIVA marker vaccines against highly pathogenic Asian H5N1 avian influenza viruses in chickens.
    Jadhao SJ; Lee CW; Sylte M; Suarez DL
    Vaccine; 2009 Oct; 27(44):6247-60. PubMed ID: 19686695
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Investigation of the biological indicator for vaccine efficacy against highly pathogenic avian influenza (HPAI) H5N1 virus challenge in mice and ferrets.
    Song MS; Oh TK; Pascua PN; Moon HJ; Lee JH; Baek YH; Woo KJ; Yoon Y; Sung MH; Poo H; Kim CJ; Choi YK
    Vaccine; 2009 May; 27(24):3145-52. PubMed ID: 19446184
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Plasmid DNA-based vaccines protect mice and ferrets against lethal challenge with A/Vietnam/1203/04 (H5N1) influenza virus.
    Lalor PA; Webby RJ; Morrow J; Rusalov D; Kaslow DC; Rolland A; Smith LR
    J Infect Dis; 2008 Jun; 197(12):1643-52. PubMed ID: 18513153
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A live attenuated H1N1 M1 mutant provides broad cross-protection against influenza A viruses, including highly pathogenic A/Vietnam/1203/2004, in mice.
    Xie H; Liu TM; Lu X; Wu Z; Belser JA; Katz JM; Tumpey TM; Ye Z
    J Infect Dis; 2009 Dec; 200(12):1874-83. PubMed ID: 19909080
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Preclinical study of influenza virus A M2 peptide conjugate vaccines in mice, ferrets, and rhesus monkeys.
    Fan J; Liang X; Horton MS; Perry HC; Citron MP; Heidecker GJ; Fu TM; Joyce J; Przysiecki CT; Keller PM; Garsky VM; Ionescu R; Rippeon Y; Shi L; Chastain MA; Condra JH; Davies ME; Liao J; Emini EA; Shiver JW
    Vaccine; 2004 Aug; 22(23-24):2993-3003. PubMed ID: 15297047
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of conserved and variable influenza antigens for immunization against different isolates of H5N1 viruses.
    Patel A; Tran K; Gray M; Li Y; Ao Z; Yao X; Kobasa D; Kobinger GP
    Vaccine; 2009 May; 27(23):3083-9. PubMed ID: 19428922
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Improved design and intranasal delivery of an M2e-based human influenza A vaccine.
    De Filette M; Fiers W; Martens W; Birkett A; Ramne A; Löwenadler B; Lycke N; Jou WM; Saelens X
    Vaccine; 2006 Nov; 24(44-46):6597-601. PubMed ID: 16814430
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Influenza-pseudotyped Gag virus-like particle vaccines provide broad protection against highly pathogenic avian influenza challenge.
    Haynes JR; Dokken L; Wiley JA; Cawthon AG; Bigger J; Harmsen AG; Richardson C
    Vaccine; 2009 Jan; 27(4):530-41. PubMed ID: 19026705
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Preparing for a possible pandemic: influenza A/H5N1 vaccine development.
    Keitel WA; Atmar RL
    Curr Opin Pharmacol; 2007 Oct; 7(5):484-90. PubMed ID: 17644429
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mutant influenza A virus nucleoprotein is preferentially localized in the cytoplasm and its immunization in mice shows higher immunogenicity and cross-reactivity.
    Ohba K; Yoshida S; Zahidunnabi Dewan M; Shimura H; Sakamaki N; Takeshita F; Yamamoto N; Okuda K
    Vaccine; 2007 May; 25(21):4291-300. PubMed ID: 17403560
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.